Seino Y, Kuwata H, Yabe D. Incretin-based drugs for type 2 diabetes: Focuson East Asian perspectives. J Diabetes Investig. 2016;7:102–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yabe D, Seino Y, Fukushima M, Seino S. β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep. 2015;15:602.

Article  PubMed  Google Scholar 

Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56:696–708.

Article  CAS  PubMed  Google Scholar 

Kim YG, Hahn S, Oh TJ, Park KS, Cho YM. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:900–9.

Article  CAS  PubMed  Google Scholar 

Drucker DJ. The GLP-1 journey: from discovery science to therapeutic impact. J Clin Invest. 2024;134: e175634.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT, McMurray JJV, Rossing P, Bakris G, Mahaffey KW, Mann JFE, Colhoun HM, Tuttle KR, Pratley RE, Perkovic V. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13:15–28.

Article  PubMed  Google Scholar 

Bae JH, Cho YM. Incretin hormones: revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity. J Diabetes Investig. 2025;16:183–6.

Article  CAS  PubMed  Google Scholar 

Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10:623–33.

Article  CAS  PubMed  Google Scholar 

Kadowaki T, Chin R, Ozeki A, Imaoka T, Ogawa Y. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10:634–44.

Article  CAS  PubMed  Google Scholar 

Yabe D, Kawamori D, Seino Y, Oura T, Takeuchi M. Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy). Diabetes Obes Metab. 2023;25:398–406.

Article  CAS  PubMed  Google Scholar 

Suzuki T, Sato T, Tanaka M, Endo K, Nakata K, Ogawa T, Hosaka I, Akiyama Y, Umetsu A, Furuhashi M. Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus. J Diabetes Complications. 2024;38: 108779.

Article  CAS  PubMed  Google Scholar 

Matsushiro M, Yamaguchi Y,Kuwata H, Hamamoto Y, Seino Y, Yamazaki Y. Short-termoutcomes of switching from GLP-1 receptor agonists totirzepatide in type 2 diabetes: a retrospective, observationalstudy in clinical practice. Diabetes Obes Metab. 2025;1–4.

The Committee on the Safe Use of Medications of the Japan Diabetes Society. Recommendations for the Safe Use of Incretin-Related Agents, Second Edition. the Japan Diabetes Society; 2024. https://www.jds.or.jp/uploads/files/recommendation/incretin.pdf. Accessed 8 Mar 2025.

Usui R, Yabe D, Kuwata H, Fujiwara S, Watanabe K, Hyo T, Yasuhara A, Iwasaki M, Kitatani N, Kuwabara K, Yokota K, Kurose T, Seino Y. Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: a caution against inappropriate use in patients with reduced β-cell function. J Diabetes Investig. 2013;4:585–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yabe D, Eto T, Shiramoto M, Irie S, Murotani K, Seino Y, Kuwata H, Kurose T, Seino S, Ahrén B, Seino Y. Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: a randomized, open-label, 2-arm parallel comparative, exploratory trial. Diabetes Obes Metab. 2017;19:442–7.

Article  CAS  PubMed  Google Scholar 

Suzuki K, Akiyama M, Ishigaki K, Kanai M, Hosoe J, Shojima N, Hozawa A, Kadota A, Kuriki K, Naito M, Tanno K, Ishigaki Y, Hirata M, Matsuda K, Iwata N, Ikeda M, Sawada N, Yamaji T, Iwasaki M, Ikegawa S, Maeda S, Murakami Y, Wakai K, Tsugane S, Sasaki M, Yamamoto M, Okada Y, Kubo M, Kamatani Y, Horikoshi M, Yamauchi T, Kadowaki T. Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population. Nat Genet. 2019;51:379–86.

Article  CAS  PubMed  Google Scholar 

Han E, Park HS, Kwon O, Choe EY, Wang HJ, Lee YH, Lee SH, Kim CH, Kim LK, Kwak SH, Park KS, Kim CS, Kang ES. A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes. Medicine. 2016;95: e5155.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuwata H, Okamoto S, Seino Y, Murotani K, Tatsuoka H, Usui R, Hamamoto Y, Kurose T, Seino Y, Yabe D. Relationship between deterioration of glycated hemoglobin-lowering effects in dipeptidyl peptidase-4 inhibitor monotherapy and dietary habits: retrospective analysis of Japanese individuals with type 2 diabetes. J Diabetes Investig. 2018;9:1153–8.

Article  CAS  PubMed  Google Scholar 

Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002;8:738–42.

Article  CAS  PubMed  Google Scholar 

Zhou BF, Stamler J, Dennis B, Moag-Stahlberg A, Okuda N, Robertson C, Zhao L, Chan Q, Elliott P; INTERMAP Research Group. Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, and United States in the late. the INTERMAP study. J Hum Hypertens. 1990;2003(17):623–30.

Google Scholar 

Terauchi Y, Yamada Y, Ishida H, Ohsugi M, Kitaoka M, Satoh J, Yabe D, Shihara N, Seino Y. Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial). Diabetes Obes Metab. 2017;19:1188–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe? J Diabetes Investig. 2014;5:475–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seino S, Zhang CL, Shibasaki T. Sulfonylurea action re-revisited. J Diabetes Investig. 2010;1:37–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang CL, Katoh M, Shibasaki T, Minami K, Sunaga Y, Takahashi H, Yokoi N, Iwasaki M, Miki T, Seino S. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science. 2009;325:607–10.

Article  CAS  PubMed  Google Scholar 

Takahashi T, Shibasaki T, Takahashi H, Sugawara K, Ono A, Inoue N, Furuya T, Seino S. Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A. Sci Signal. 2013;6(298): ra94.

Takahashi H, Shibasaki T, Park JH, Hidaka S, Takahashi T, Ono A, Song DK, Seino S. Role of Epac2A/Rap1 signaling in interplay between incretin and sulfonylurea in insulin secretion. Diabetes. 2015;64:1262–72.

Article  CAS  PubMed  Google Scholar 

Dicembrini I, Montereggi C, Nreu B, Mannucci E, Monami M. Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2020;159: 107981.

Article  CAS  PubMed  Google Scholar 

Yabe D, Kuwata H, Kaneko M, Ito C, Nishikino R, Murorani K, Kurose T, Seino Y. Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs. Diabetes Obes Metab. 2015;17:430–4.

Article  CAS  PubMed  Google Scholar 

Kubota S, Haraguchi T, Kuwata H, Seino Y, Murotani K, Tajima T, Terashima G, Kaneko M, Takahashi Y, Takao K, Kato T, Shide K, Imai S, Suzuki A, Terauchi Y, Yamada Y, Seino Y, Yabe D. Association of dipeptidyl peptidase-4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan. J Diabetes Investig. 2023;14:67–74.

Article  CAS  PubMed  Google Scholar 

Shapiro SB, Yin H, Yu OHY, Azoulay L. Dipeptidyl peptidase-4 inhibitors and the risk of gallbladder and bile duct disease among patients with type 2 diabetes: a population-based cohort study. Drug Saf. 2024;47:759–69.

Article  CAS  PubMed  Google Scholar 

Yoshiji S, Murakami T, Harashima SI, Ko R, Kashima R, Yabe D, Ogura M, Doi K, Inagaki N. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases. J Diabetes Investig.